期刊文献+

CCR5在炎症性肠病患者肠黏膜的表达及其与β-arrestin2表达的关系 被引量:5

Correlation of CCR5 expression with β-arrestin 2 expression in colonic mucosa of patients with inflammatory bowel disease
下载PDF
导出
摘要 目的:通过分析CCR5在炎症性肠病(IBD)患者活检肠黏膜的表达及其与β-arrestin 2表达的相关性,探讨CCR5与β-arrestin 2在IBD发病中的作用。方法:IBD活动期组53例、IBD缓解期组26例和正常对照组30例纳入研究,用En Vision二步免疫组化方法检测活检肠黏膜CCR5和β-arrestin 2的表达。结果:IBD活动期组CCR5阳性表达率及免疫组化评分均高于正常对照组和IBD缓解期组(P<0.05),CCR5表达与IBD活动期组的临床严重程度、病变范围及内镜下分级无明显关联性;β-arrestin 2在IBD活动期组的阳性表达率均明显低于IBD缓解期组和正常对照组(P<0.05),并且在IBD活动期β-arrestin 2表达与CCR5表达呈负相关性(P<0.05)。结论:在IBD活动期组肠黏膜CCR5呈高表达,β-arrestin 2呈明显低表达,CCR5与β-arrestin 2表达呈负相关性。 AIM: To analyze the expression of CCR5 and correlation with the expression of β-arrestin 2 in the intestinal mucosa of the patients with inflammatory bowel disease( IBD),so as to study the role of CCR5 and β-arrestin 2in the pathogenesis of IBD. METHODS: Paraffin sections of the colonic mucosa were prepared from 53 patients with active IBD,26 patients with remissive IBD and 30 healthy people. Immunohistochemical En Vision two-step method was used to test the expression of CCR5 and β-arrestin 2 in the biopsic intestinal mucosa. RESULTS: The positive rate,strongly positive rate and immunohistochemical score of CCR5 expression in active IBD were significantly higher than those in normal controls or remissive IBD( P 0. 05). No correlation of CCR5 expression with clinical severity,lesion distribution,and endoscopic grade in active IBD was observed. The expression of β-arrestin 2 was significantly lower in active IBD than that in the remissive IBD and normal controls,and there was a negative correlation of β-arrestin 2 expression with CCR5 expression( P 0. 05). CONCLUSION: The expression of CCR5 is higher,and expression of β-arrestin 2 is lower,and there is a negative correlation of expression of CCR5 with expression of β-arrestin 2 in intestinal mucosa of the active IBD.
出处 《中国病理生理杂志》 CAS CSCD 北大核心 2016年第4期713-718,共6页 Chinese Journal of Pathophysiology
基金 国家自然科学基金资助项目(No.81370499) 广东省自然科学基金资助项目(No.2014A030313020)
关键词 炎症性肠病 CCR5 Β-ARRESTIN 2 Inflammatory bowel disease CCR5 β-arrestin 2
  • 相关文献

参考文献25

  • 1叶小研,钟英强.CC趋化因子受体与炎症性肠病[J].胃肠病学,2014,19(1):50-53. 被引量:7
  • 2Ajuebor MN, Hogaboam CM, Kunkel SL, et at. The che- mokine RANTES is a crucial mediator of the progression from acute to chronic colitis in the rat [ J]. J Immunol, 2001, 166 ( 1 ) :552-558.
  • 3Kucuk C, Sozuer E, Gursoy S, et al. Treatment with Met- RANTES decreases bacterial translocation in experimental colitis[J]. Am J Surg, 2006, 191(1): 77-83.
  • 4Tokuyama H, Ueha S, Kurachi M, et at. The simuhane- ous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis [J]. Int Immunol, 2005, 17 (8):1023-1034.
  • 5Mellado M, Rodriguez-Frade JM, Vila-Coro AJ, et at. Chemokine receptor homo- or heterodimerization activates distinct signaling pathways [ J ]. EMBO J, 2001, 20 (10) :2497-2507.
  • 6Sasaki S, Baba T, Shinagawa K, et at. Crucial involve- ment of the CCL3-CCR5 axis-mediated fibroblast accumu- lation in colitis-associated carcinogenesis in mice [ J ]. Int J Cancer,2014, 135(1) :1-10.
  • 7Ganju RK, Dutt P, Lijun Wu,et al. [3-Chemokine receptor CCR5 signals via the novel tyrosine kinase RAPTK [ J ]. Blood, 1998, 91 (3) :791-797.
  • 8Chuang JY, Yang WH, Chen HT, et al. CCLS/CCR5 axis promotes the motility of human oraleancer cells[ J]. J Cell Physiol, 2009, 220 ( 2 ) :418-426.
  • 9Wong M, Uddin S, Majchrzak B, et al. RANTES activates Jak2 and Jak3 to regulate engagement of multiple signaling pathways in T cells [ J]J Biol Chem, 2001, 276 (14) : 11427-11431.
  • 10无,胡品津.炎症性肠病诊断与治疗的共识意见(2012年,广州)[J].中华消化杂志,2012,32(12):796-813. 被引量:531

二级参考文献72

  • 1高翔,胡品津,何瑶,廖山婴,彭穗,陈旻湖.炎症性肠病患者血清中自身抗体检测的临床意义[J].中华内科杂志,2005,44(6):428-430. 被引量:39
  • 2刘思德,姜泊,周殿元.放大内镜结合黏膜染色技术诊断溃疡性结肠炎——附116例放大内镜形态分析[J].现代消化及介入诊疗,2005,10(2):116-118. 被引量:8
  • 3李亚红,韩英,吴开春.炎症性肠病危险因素的流行病学调查研究[J].胃肠病学和肝病学杂志,2006,15(2):161-162. 被引量:19
  • 4Koenecke C,F(o)rster R. CCR9 and inflammatory bowel disease[J].{H}EXPERT OPINION ON THERAPEUTIC TARGETS,2009,(3):297-306.
  • 5Sallusto F,Lanzavecchia A,Mackay CR. Chemokines and chemokine receptors in T-cell priming and Thl/Th2-mediated responses[J].{H}Immunology Today,1998,(12):568-574.
  • 6Boring L,Gosling J,Chensue SW. Impaired monocyte migration and reduced type 1 (Th1) cytokine responses in C-C chemokine receptor 2 knockout mice[J].{H}Journal of Clinical Investigation,1997,(10):2552-2561.
  • 7Andres PG,Beck PL,Mizoguchi E. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis:lack of CC chemokine receptor 5 expression results in a NK1.1 + lymphocyte-associated Th2-type immune response in the intestine[J].{H}Journal of Immunology,2000,(12):6303-6312.
  • 8Thomas S,Baumgart DC. Targeting leukocyte migration and adhesion in Crohn' s disease and ulcerative colitis[J].{H}INFLAMMOPHARMACOLOGY,2012,(1):1-18.
  • 9Popivanova BK,Kostadinova FI,Furuichi K. Blockade of a chemokine,CCL2,reduces chronic colitisassociated carcinogenesis in mice[J].{H}CANCER RESEARCH,2009,(19):7884-7892.
  • 10Connor SJ,Paraskevopoulos N,Newman R. CCR2 expressing CD4 + T lymphocytes are preferentially recruited to the ileum in Crohn's disease[J].{H}GUT,2004,(9):1287-1294.

共引文献545

同被引文献80

  • 1王红军,庒贵华,郑见宝.缺血预处理对大鼠小肠移植后肠黏膜的保护作用[J].西安交通大学学报(医学版),2012,33(2):185-189. 被引量:2
  • 2王立明,郑灵,秦荣,张朝军,马丹,向佳梅.结肠癌细胞中氧自由基含量的临床测定[J].重庆医学,2005,34(2):265-266. 被引量:9
  • 3王晓颖,樊嘉,周俭,邱双健,余耀,刘银坤,汤钊猷.CCR1趋化因子受体在人肝癌组织中表达及其临床意义[J].中华肝胆外科杂志,2006,12(2):101-104. 被引量:20
  • 4Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
  • 5Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaib]e TF, van Deventer SJ. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340:1398-1405.
  • 6Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476.
  • 7Hyams JS, Lerer T, Griffiths A, Pfefferkorn M, Kugathasan S, Evans J, Otley A, Carvalho R, Mack D, Bousvaros A, Rosh J, Mamula P, Kay M, Crandall W, Oliva-Hemker M, Keljo D, LeLeiko N, Markowitz J. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. InJlamm Bowel Dis 2009; 15:816-822.
  • 8Sandborn WJ, van Assche G, Reinisch W, Colombel JF, D'Haens G, Wolf DC, Kron IV[, Tighe MB, Lazar A, Thakkar RB. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142:257-265.e1-3.
  • 9Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146:829-838.
  • 10Hyams JS, Griffiths A, Markowitz J, Baldassano RN, Faubion WA, Colletti RB, Dubinsky M, Kierkus J, Rosh J, Wang Y, Huang B, Bittle B, Marshall M, Lazar A. Safety and efficacy of adalimumab for moderate to severe Crohn'sdisease in children. Gastroenterology 2012; 143: 365-374.e2.

引证文献5

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部